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Abstract: Background: We hypothesized that treatment with quercetin could result in improved
hemodynamics, lung inflammatory parameters and mortality in a rat model of hemorrhagic shock.
Methods: Rats were anesthetized (80 mg/kg ketamine plus 8 mg/kg xylazine i.p.). The protocol
included laparotomy for 15 min (trauma), hemorrhagic shock (blood withdrawal to reduce the mean
arterial pressure to 35 mmHg) for 75 min and resuscitation by re-infusion of all the shed blood
plus lactate Ringer for 90 min. Intravenous quercetin (50 mg/kg) or vehicle were administered
during resuscitation. Results: There was a trend for increased survival 84.6% (11/13) in the treated
group vs. the shock group 68.4% (13/19, p > 0.05 Kaplan–Meier). Quercetin fully prevented the
development of lung edema. The activity of aSMase was increased in the shock group compared
to the sham group and the quercetin prevented this effect. However, other inflammatory markers
such as myeloperoxidase activity, interleukin-6 in plasma or bronchoalveolar fluid were similar in
the sham and shock groups. We found no bacterial DNA in plasma in these animals. Conclusions:
Quercetin partially prevented the changes in blood pressure and lung injury in shock associated to
hemorrhage and reperfusion.
Keywords: systemic arterial pressure; lung edema; hemorrhage; trauma; reperfusion
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1. Introduction
Severe trauma is a leading cause of death and disability worldwide [1]. Hemorrhagic shock after
a severe blood loss associated with trauma results in a state of global ischemia. Hemorrhage is managed
by fluid resuscitation with crystalloid fluids and blood products which restore the circulating volume
and cardiac output [2]. During the reperfusion phase, cell damage induced by ischemia is enhanced
due to excessive production of radical oxygen species—a systemic inflammatory response—apoptosis
and necrosis, eventually leading to multiple organ failure [3,4]. Thus, global ischemia and the
post-reperfusion inflammatory response in hemorrhagic shock are the initial triggering events for
the development of acute respiratory distress syndrome (ARDS), a major cause of death in trauma
patients. There are no effective treatments that reduce the mortality associated to ARDS, except the
hemodynamic and ventilatory support protective strategies [5]. Therefore, the identification of new
drugs preventing the ischemia-reperfusion damage could improve survival in patients with trauma.
The flavonoid quercetin is one of the most abundant polyphenolic compounds. It belongs to the
subclass of flavonols, is widely distributed in plants and is found naturally in a number of foods in the
human diet (including apples, onions, teas, berries, and red wine), in some herbs and it is also available
as a dietary supplement. It exerts a wide range of biological actions, including antioxidant, anti-platelet,
anti-inflammatory, vasodilator and antihypertensive effects [6–8]. Quercetin decreased systemic
inflammation and reduced mortality in animal models of lethal endotoxemia [9]. The authors attributed
this effect of quercetin to the inhibition of high mobility group box 1 (HMGB1), a crucial nuclear
cytokine that elicits severe vascular inflammatory diseases. Activation of acid sphingomyelinase may
play a role in endotoxin- and lavage-induced lung injury [10,11] but the effects of quercetin on this
signaling pathway are unknown.
Therefore, we hypothesized that quercetin could result in improved hemodynamics, inflammatory
parameters and mortality in a rat model of traumatic hemorrhagic shock. The aim of our study is to
determine whether the administration of quercetin during resuscitation prevents mortality, systemic
and pulmonary inflammatory response and aSMase activation associated to acute lung injury induced
by traumatic hemorrhagic shock.
2. Results
2.1. Mortality
In the shock group, the survival rate at the end of the reperfusion period was 68.4% (13/19) which
was significantly lower than in the sham group (100%). In the treated group (shock + quercetin) the
survival rate was 84.6% (11/13) (Figure 1). Despite a favorable trend, the Kaplan–Meier analysis
indicated no significant differences in survival between the treated group vs. the shock group.
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Figure 1. Kaplan–Meier survival analysis during the reperfusion period. Anaesthetized animals were 
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Figure 1. Kaplan–Meier survival analysis during the reperfusion period. Anaesthetized animals were
submitted to shock and at time 90 they were reperfused with blood plus lactate Ringer and with vehicle
or quercetin, and followed for an additional period of 90 min. * p < 0.05 vs. sham (log-rank test).
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2.2. Arterial Pressure and Heart Rate
Figure 2A shows the changes in the mean arterial pressure in all groups. The laparotomy
induced a significant reduction of the arterial pressure (at 15 min) and a sustained hypotension (shock
phase) was achieved by bleeding the animals to a target pressure of 35 mmHg (from 15 to 90 min).
The reperfusion produced an initial transient hypertension during the reinfusion period of the blood
plus lactate Ringer, followed by a hypotensive phase. The hypertensive phase was less marked in the
animals treated with quercetin. Figure 2B shows that during the shock period, an increase in heart rate
was observed in some animals but, taken together, differences were not statistically different among
groups. In the reperfusion phase, heart rate was similar in all groups.
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Figure 2. Changes in (A) mean arteri l l re and (B) heart rate in the thre experimental
groups. Rats were subjected to laparoto f ll e controlled hypotension (shock phase) and then
by resuscitation with lactate Ringer solution, shed blood and the quercetin or vehicle. Data are shown
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2.3. Acid Sphingomyelinase Activity
At the end of the reperfusion period, aSMase activity was increased in lung homogenates from the
animals exposed to traumatic shock and resuscitation (Figure 3). Quercetin prevented the activation of
the enzyme.
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2.4. Blood Gases
After 90 min of shock, animals developed metabolic acidosis with a decrease in pH (7.19 ± 0.02 vs.
7.32± 0.02 in the sham group), excess base (−10.5± 1.2 vs. −2.8± 1.3 mEq/L), bicarbonate (17.2 ± 1.2
vs. 23.3 ± 1.2 mmol/L), TCO2 (18.4 ± 1.3 vs. 24.5 ± 1.1 mmol/L) (p < 0.05 for all parameters, Student’s
t test) without changes in SO2 and pCO2. At the end of the reperfusion period, the values of pH, pCO2,
base excess, bicarbonate and TCO2 in the shock group were restored (p > 0.05 vs. the sham group,
Figure 4A–E) but animals developed hypoxemia with a significant decrease in pO2 and a similar trend
for SO2 (Figure 4F,G). The hypoxemia induced by shock and reperfusion was not reverted by quercetin.
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2.5. Electrolytes, Hematocrit and Hemoglobin
At the end of shock phase, an increase in plasma potassium and a moderate decrease in sodium
were observed in the shock group with no changes in plasma calcium. Anemia, resulting from
hemorrhage during the shock phase, was reverted after the reinfusion period. Electrolyte, hematocrit
and hemoglobin values at the end of reperfusion were similar in all groups (Table 1).
Table 1. Electrolytes, hematocrit and hemoglobin (Hb).
Group
Shock Phase (t = 90 min) Reperfusion (t = 180 min)
Na K Ca Hb Hematocrit Na K Ca Hb Hematocrit
Sham 137.4± 0.82
5.30 ±
0.13
1.28 ±
0.05
13.38
± 0.37 39.40 ± 1.07
137.0
± 2.84
5.10 ±
0.16
1.19 ±
0.11
12.62
± 0.33 37.11 ± 0.95
Shock 132.0 **± 0.85
6.33 **
± 0.26
1.18 ±
0.12
9.50 **
± 0.50 27.88 ** ± 1.47
131.79
± 2.37
5.84 ±
0.17
0.95 ±
0.09
11.59
± 0.37 34.07 ± 1.09
Shock + quercetin nd nd nd nd nd 133.36± 1.52
5.40 ±
0.17
1.18 ±
0.12
12.93
± 0.42 38.00 ± 1.22
** p < 0.01 vs. sham (Student’s t test). The one-way Anova indicated no significant differences during reperfusion.
2.6. Markers of Inflammation, Pulmonary Vascular Permeability, Histological Changes and Bacterial Translocation
Figure 5A shows that animals submitted to shock plus reperfusion develop pulmonary edema,
as indicated by an increase in the wet to dry lung weight ratio. Quercetin inhibited the development
of edema. Proteins in bronchoalveolar lavage fluid (BALF) and IgM, used as markers of pulmonary
vascular permeability, increased in the shock compared to the sham group (Figure 5B,C). Paradoxically,
quercetin increased the proteins levels and IgM concentration in BALF. Cell counting in BALF and
the myeloperoxidase activity in lung homogenates were not significant among groups (Figure 5D,E).
IL-6 concentration in BALF (Figure 5F) or in plasma (not shown) was similar between sham and
shock groups.
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To analyze bacterial translocation, DNA in plasma was determined using specific primers for
conserved regions of bacterial 16S gene. We found no bacterial DNA in plasma in any groups,
indicating the lack of bacterial translocation.
3. Discussion
Reperfusion-induced organ damage after hemorrhagic shock is associated to oxidative stress and
a syste ic inflammatory status, resulting in a significant mortality. At present, there is no effective
treat ent for this condition. Herein, we show that quercetin prevented partially the reperfusion
damage in a rat del of hemorrhagi raumatic shock.
Several hemorrhagic shock-resuscitation models have been established but none of them covers all
of the impo tant aspects relat d to clinical reality [12–14]. A short period of severe hypot nsion Mean
Arterial Pressure (MAP) lower than 25 to 35 mmHg for only 20 min does not result in life-threatening
organ injury and it is not clinically relevant [15]. Our experimental schedule of trauma induction within
15 min, a hemorrhagic shock period of 75 min and subsequent resuscitation for 20–30 min, is orientated
toward human clinical practice and reflects most emergency situations realistically [16]. The model
was associated, at the end of the reperfusion period, with hypotension, hypoxemia, lung edema,
increased pulmonary vascular permeability and 30% mortality. However, we found little changes in
inflammatory markers. The protocol of drug administration at the beginning of the resuscitation was
also clinically oriented in order to analyze the potential effects to prevent reperfusion-induced damage
at the Intensive Care Unit (ICU).
Rats receiving shed blood plus the same v lume of Ringer’s lactate ith quercetin during
resuscitation restored the bl od pressure af r 20–30 min. Reperfusion produc d an initial transient
hyperte sion during the reinfus on period of the blood plus lacta e Ringer. This was followed by the
characteristic f atures of s ock with associated orga injury, a hypotensive phase and hypoxemia.
Hyponatremia, hyperpotassemia and anemia were recovered by the fluid and blood re-infusion.
Quercetin prevented the hypertensive phase but did not correct the hypoxemia and hypotension
induced by shock and reperfusion. The mortality in the shock vehicle group was 30% and a trend for
increased survival in the quercetin treated group (15%) was observed.
The pulmonary edema was shown by an increase in the wet to dry lung weight ratio in the shock
group and this was accompanied by increased total proteins in BALF. Nevertheless, inflammation
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markers such as myeloperoxidase, IL-6 in BALF and in plasma and the cells infiltration in BALF
were similar in the shock and sham groups. Remarkably, quercetin prevented the formation of
edema. Paradoxically, the changes in total proteins and IgM in BALF were not prevented by quercetin.
Flavonoids were initially described to be protective on the permeability of vascular capillaries as
early as the 1930s [17]. The fact that quercetin reduced edema but not the change in proteins or IgM
suggests that the anti-edema effect is due to reduced hydrostatic pressure rather than a direct effect on
vascular permeability. This is consistent with the prevention of the hypertensive phase by quercetin
during blood and fluid administration which is presumably accompanied by reduced pulmonary
arterial pressure.
Sphingolipids are structural components of eukaryotic cellular membranes [18] whose hydrolysis
products (ceramide, sphingosine and sphingosine-1-phosphate, S1P) play a key role in signalling
pathways involved in different cellular processes, such as cell growth and differentiation, inflammation,
apoptosis and vascular tone [19]. Alteration of the sphingolipid signaling pathway may play
a pathophysiological role in several conditions, such as diabetes, atherosclerosis, chronic heart failure,
sepsis, cancer and several lung diseases including ARDS, cystic fibrosis and Chronic Obstructive
Pulmonary Disease (COPD) [18,20,21]. aSMase is a critical enzyme in sphingolipid biochemistry that,
under conditions of inflammation or stress, can rapidly be activated to convert sphingomyelin to
ceramide [22]. A well described consequence of aSMase activation is formation of ceramide-rich
membrane microdomains which are involved in several cell functions, such as stress signalling,
apoptosis after death cell receptor stimulation and infection with various pathogens [18,22].
These findings suggest that sphingolipids should be studied further as a therapeutic target in
ARDS [21]. Activation of aSMase and increased ceramide levels has been reported to play a role in
acute lung injury induced by endotoxin [10], Platelet Activating Factor (PAF) [23] and by surfactant
washout [11]. Herein, we report for the first time increased aSMase activity in lung homogenates
following traumatic hemorrhagic shock and reperfusion, thus confirming that aSMase activation is
a common feature of animal models of acute lung damage. Moreover, aSMase inhibition prevented
acute lung injury caused by PAF [23] or by repeated airway lavage [11]. We also found that quercetin
prevented the increase in lung aSMase activity. Therefore, this suggests that aSMase inhibition is
a novel potential mechanism of organ protection by quercetin.
4. Materials and Methods
4.1. Animals
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (publication No. 85–23, [24]), and the procedures were approved by
our institutional Ethical Committee. Male Wistar rats (n = 44; weight, 275 to 325 g; age, 12 weeks) were
obtained from Harlan Laboratories (Barcelona, Spain). Animals were kept under standard conditions
of temperature 22 ± 1 ◦C) and 12:12 h dark/light cycle with free access to food and water.
4.2. Anesthesia, Pressure Measurements and Blood Gases
Rats were anesthetized (80 mg/kg ketamine plus 8 mg/kg xylazine i.p.) and the carotid artery and
internal jugular vein were isolated and cannulated with polyethylene catheters (PE-50). Despite ketamine
being reported to induce disparate antioxidant/prooxidant effects depending on the dose and organs [25],
the anti-oxidant effect of quercetin has been widely reported in animals anaesthetized with the anesthetic
mixture (e.g., [26]). Both catheters remained in place for the duration of the experiment and were fixed
with surgical suture (skin). Animals remained anesthetized throughout the duration of the experiment by
continuous intravenous infusion of ketamine plus xylazine (60 and 3 µg/kg/min, respectively). Systolic,
diastolic, mean systemic arterial pressures and heart rate were analyzed with a pressure transducer
via a catheter located in the carotid artery in anesthetized rats. Blood samples were collected from
the carotid artery. Arterial oxygen saturation (SO2) was continuously recorded by a pulsioxymeter
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(StarrOx) placed in the paw of the animal. Arterial oxygen and carbon dioxide partial pressure (pO2
and pCO2, respectively), SO2, pH, acid-base status, hemoglobin concentration, hematocrit, electrolytes
(Na+, K+, Ca2+), and glucose were assessed by using a blood gas analyzer (i-Stat, Softonic, Abbott,
Madrid, Spain).
4.3. Study Groups and Protocol
Animals were randomly allocated to three experimental groups (n = 11–20 in each one): (1) sham
group plus vehicle (100 µL DMSO, sham); (2) shock plus vehicle (shock); (3) shock + quercetin
(50 mg/kg). The temperature of the animals was maintained at approximately 37 ◦C, using an electric
heating pad under the surgical platform. After surgery, rats were stabilized for 10 min. Rats in the
sham group were followed for 180 min and vehicle was administered at time 90 min (100 µL DMSO
infused manually over a period of 5 min). Rats in the shock groups were submitted to a protocol of
trauma plus hemorrhagic shock followed by resuscitation [26]. Briefly, a 3 cm midline laparotomy
was performed with exposure of the intestine for 15 min (trauma), followed by reintroduction and
closure with a 4–0 silk suture. Hemorrhagic shock was induced by blood withdrawal in order to
reduce the mean arterial pressure to 35 mmHg and maintained at this level for 75 min by withdrawing
or re-infusing blood as needed. At the end of the hemorrhagic shock (time 90 min), the animals were
resuscitated by re-infusion of all the shed blood plus the same volume of lactate Ringer (over a period
of approx. 20–30 min) restoring the blood pressure [27,28]. Quercetin was administered intravenously
(50 mg/kg). Eventually, the time of death was recorded for survival analysis. Blood samples were
taken from the carotid artery catheter at time 15 (after trauma), 90 (at the end of the shock period)
and 180 min (end of the experiment). Blood plasma was obtained by centrifugation (1000 rpm,
15 min, RT) and stored at −80 ◦C until use. At the end of the experiment, surviving animals
were sacrificed by a tracheotomy and thoracotomy performed by midline incision and the right
bronchium was ligated. Ten mL cold saline solution (0.9% NaCl, 2.5 mL four times) was administered
intratracheally; then, 7–8 mL of bronchoalveolar lavage fluid (BALF) was collected and centrifuged
(1500 rpm, 10 min, RT) for the determination of the following parameters: cell number (106/mL) and
phenotype, lung permeability, protein (mg/mL), interleukin-6 (IL-6) (pg/mL) and immunoglobulin M
(IgM) concentration. In a subset of the animals, two lobes of the right lung were collected and placed
in liquid nitrogen until storage at −80 ◦C to analyze changes in lung vascular permeability and to
measure the activity of the acid sphingomyelinase and myeloperoxidase enzymes as markers of the
inflammatory process. The other lobe of the right lung was weighed and put in a laboratory oven
at 50 ◦C for 24 h in order to determine pulmonary edema by calculating the lung wet-to-dry (W/D)
weight ratio (W/D). In the other subset, the lungs were used for histopathologic evaluation.
4.4. Myeloperoxidase Activity Assay (MPO)
MPO activity was measured in frozen lung tissue, homogenized in pestle and mortar with liquid
nitrogen and then with a pellet pestle motor for 30 s (0.1 g of lung/500 µL phosphate buffer) and
centrifuged (20 min, 13,000 rpm at 4 ◦C). The pellet was resuspended in 300 µL of phosphate buffer
containing 0.5% hexadecyltrimethylammonium bromide (CTAB) and subjected to three cycles of
sonication, freezing and thawing prior to a final centrifugation step. The supernatant generated
was assayed for MPO activity using kinetic readings over 12 min at 450 nm (10 µL sample with
100 µL solution containing 0.167 mg·mL−1 of O-dianisidine dihydrochloride and 0.0006% H2O2).
MPO activity was evaluated in 4 µg of protein for each sample and expressed as MPO/min/µg
of proteins.
4.5. Acid Sphingomyelinase Assay (aSMase)
Acid sphingomyelinase activity was measured using a commercial fluorimetric assay kit
(Cayman). Briefly, aSMase was determined in lung homogenate using an aSMase solution provided
by the kit (50 mM sodium acetate, pH = 5; 0.01 g of lung/100 µL aSMase solution). After incubation
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on ice for 15 min, the homogenate was centrifuged (2780 rpm, 4 ◦C, 10 min). The supernatant was
collected and sonicated (5 s) and aSMase activity was analyzed using the fluorometer Varioskan
(Thermo Scientific, excitation and emission wavelengths of 535 and 590 nm, respectively). The activity
was determined in 36 µg protein and expressed as nmol/min/mL [11].
4.6. Bacterial Translocation
DNA was isolated from plasma (200 µL) using a QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions and amplified by quantitative RT-PCR using
a Taqman system (Roche-Applied Biosystems, Mennheim, Germany) in the Genomic Unit of University
Complutense of Madrid. Specific primers and a probe were designed for the conserved regions of
bacterial 16S rDNA: the forward primer, 5′-TCCTACGGGAGGCAGCAGT-3′, the reverse primer
5′GGACTACCAGGGTATCTA ATCCTGTT-3′ and the probe (6-FAM)-5′-CGTATTACCGCGGCTGCT
GGCAC-3′-(TAMRA) [29]. E. coli DNA was used as a positive control.
4.7. Cytokine and IgM Assay
IL-6 and IgM concentrations were determined in plasma (dilution 1:10 and dilution 1:2000
respectively) and in BALF (dilution 1:5 for IgM) using ELISA Kits (DuoSet ELISA Development
Systems-Research and Development System, Rat IgM Ready-Set-go, Affimetrix).
4.8. Statistical Analysis
Results are expressed as means ± SEM of measurements or as medians with interquartile range
and minimum and maximum values in a box-and-whisker plot. Survival graphs were constructed
according to the Kaplan–Meier method, and the log-rank test was used to compare curves. For normally
distributed data, statistical analysis was performed by one-way ANOVA and subsequent Dunnett’s
post hoc test (except for two sample comparisons at time 90 min which were analyzed by a Student’s
t test). Otherwise, a non-parametric Kruskal–Wallis test followed by Dunn’s multiple comparison test
was used. A value of p < 0.05 was considered statistically significant.
5. Conclusions
In conclusion, quercetin presents a partial protective effect in this shock–trauma model, preventing
the activation of aSMase and inhibiting the development of edema. Moreover the hypertensive phase
was less marked in the animals treated with quercetin. Given the lack of effective treatments for this
severe condition, together with a favorable safety profile of this flavonoid, we suggest that quercetin
might be useful in patients at risk of ischaemia reperfusion injury following reperfusion in patients
suffering a hemorrhagic shock.
Acknowledgments: Supported by Fundación Mutua Madrileña (AP102962012), Spanish MINECO (SAF 2011-28150;
SAF2014-55399R; SAF2014-58920) and ISCIII (CP12/03304, FIS 15/1492).
Author Contributions: F.P-V. conceived and designed the experiments; V.C., R.P., L.M., B.B., A.M., and
D.M.-C. performed the experiments and analyzed the data; A.C., J.D., J.R.-C, J.A.L. and J.L.A.-S. contributed
reagents/materials/analysis tools and contributed to the paper discussion; V.C., R.P., A.C., L.M. and F.P.-V. wrote
the paper.
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results.
References
1. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.;
Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:
A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095–2128. [CrossRef]
Molecules 2016, 21, 1739 10 of 11
2. Finfer, S.; Liu, B.; Taylor, C.; Bellomo, R.; Billot, L.; Cook, D.; Du, B.; McArther, C.; Myburgh, J. Resuscitation
fluid use in critically ill adults: An international cross-sectional study in 391 intensive care units. Crit. Care
2010, 14, R185. [CrossRef] [PubMed]
3. Collard, C.D.; Gelman, S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury.
Anesthesiology 2001, 94, 1133–1138. [CrossRef] [PubMed]
4. Rushing, G.D.; Britt, L.D. Reperfusion injury after hemorrhage: A collective review. Ann. Surg. 2008, 247,
929–937. [CrossRef] [PubMed]
5. Cortés, I.; Peñuelas, O.; Esteban, A. Acute respiratory distress syndrome: Evaluation and management.
Minerva Anestesiol. 2012, 78, 343–357. [PubMed]
6. Pérez-Vizcaíno, F.; Ibarra, M.; Cogolludo, A.L.; Duarte, J.; Zaragozá-Arnáez, F.; Moreno, L.; López-López, G.;
Tamargo, J. Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated
metabolites in rat conductance and resistance arteries. J. Pharmacol. Exp. Ther. 2002, 302, 66–72. [CrossRef]
[PubMed]
7. Perez-Vizcaino, F.; Duarte, J.; Jimenez, R.; Santos-Buelga, C.; Osuna, A. Antihypertensive effects of the
flavonoid quercetin. Pharmacol. Rep. 2009, 61, 67–75. [CrossRef]
8. Perez-Vizcaino, F.; Duarte, J. Flavonols and cardiovascular disease. Mol. Asp. Med. 2010, 31, 478–494.
[CrossRef] [PubMed]
9. Tang, D.; Kang, R.; Xiao, W.; Zhang, H.; Lotze, M.T.; Wang, H.; Xiao, X. Quercetin prevents LPS-induced
high-mobility group box 1 release and proinflammatory function. Am. J. Respir. Cell Mol. Biol. 2009, 41,
651–660. [CrossRef] [PubMed]
10. Pandolfi, R.; Barreira, B.; Moreno, E.; Lara-Acedo, V.; Morales-Cano, D.; Martínez-Ramas, A.;
de Olaiz Navarro, B.; Herrero, R.; Lorente, J.A.; Cogolludo, A.; et al. Role of acid sphingomyelinase and IL-6
as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax 2016. [CrossRef] [PubMed]
11. Von Bismarck, P. Improved Pulmonary Function by Acid Sphingomyelinase Inhibition in a Newborn Piglet
Lavage Model. Am. J. Respir. Crit. Care Med. 2008, 177, 1233–1241. [CrossRef] [PubMed]
12. Russell, D.H.; Barreto, J.C.; Klemm, K.; Miller, T.A. Hemorrhagic shock increases gut macromolecular
permeability in the rat. Shock 1995, 4, 50–55. [CrossRef] [PubMed]
13. Yang, R.; Harada, T.; Mollen, K.P.; Prince, J.M.; Levy, R.M.; Englert, J.A.; Gallowitsch-Puerta, M.; Yang, L.;
Yang, H.; Tracey, K.J.; et al. AntiHMGB1 neutralizing antibody ameliorates gut barrier dysfunction and
improves survival after hemorrhagic shock. Mol. Med. 2006, 12, 105–114. [CrossRef] [PubMed]
14. Zhong, Z.; Enomoto, N.; Connor, H.D.; Moss, N.; Mason, R.P.; Thurman, R.G. Glycine improves survival
after hemorrhagic shock in the rat. Shock 1999, 12, 54–62. [CrossRef] [PubMed]
15. Stein, H.J.; Hinder, R.A.; Oosthuizen, M.M.J. Gastric mucosal injury caused by hemorrhagic shock and
reperfusion: Protective role of the antioxidant glutathione. Surgery 1990, 108, 467–473. [PubMed]
16. Hussmann, B.; Taeger, G.; Lefering, R.; Waydhas, C.; Nast-Kolb, D.; Ruchholtz, S.; Lendemans, S.
Trauma register der Deutschen Gesell-schaft für Unfallchirurgie. Lethality and outcome in multiple injured
patients after severe abdominal and pelvic trauma: Influence of preclinical volume replacement-an analysis
of 604 patients from the trauma registry of thr DGU. Unfallchirung 2011, 114, 705–712.
17. Rusznyak, S.; Szent-Györgyi, A. Vitamin P: Flavonols as vitamins. Nature 1936, 138, 27–29. [CrossRef]
18. Gulbins, E.; Li, P.L. Physiological and pathophysiological aspects of ceramide. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 2006, 290, R11–R26. [CrossRef] [PubMed]
19. Frazziano, G.; Moreno, L.; Moral-Sanz, J.; Menendez, C.; Escolano, L.; Gonzalez, C.; Villamor, E.;
Alvarez-Sala, J.L.; Cogolludo, A.L.; Perez-Vizcaino, F. Neutral sphingomielinase, NADPH oxidase and reactive
oxygen species. Role in acute hypoxic pulmonary vasoconstriction. J. Cell Physiol. 2011, 226, 2633–2640.
[CrossRef] [PubMed]
20. Larsen, P.J.; Tennagel, N. On ceramides, other sphingolipids and impaired glucose homeostasis. Mol. Metab.
2014, 3, 252–260. [CrossRef] [PubMed]
21. Tibboel, J.; Reiss, I.; de Jongste, J.C.; Post, M. Sphingolipids in Lung Growth and Repair. Chest 2014, 145,
120–128. [CrossRef] [PubMed]
22. Uhlig, S.; Gulbins, E. Sphingolipids in the lungs. Am. J. Respir. Crit. Care Med. 2008, 178, 1100–1114.
[CrossRef] [PubMed]
Molecules 2016, 21, 1739 11 of 11
23. Göggel, R.; Winoto-Morbach, S.; Vielhaber, G.; Imai, Y.; Lindner, K.; Brade, L.; Brade, H.; Ehlers, S.;
Slutsky, A.S.; Schütze, S.; et al. PAF-mediated pulmonary edema: A new role for acid sphingomyelinase
and ceramide. Nat. Med. 2004, 10, 155–160. [CrossRef] [PubMed]
24. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory
Animal Research, Division on Earth and Life Studies, National Research Council. Guide for the Care and Use
of Laboratory Animals; National Academies Press: Washington, DC, USA, 2011.
25. De Oliveira, L.; Spiazzi, C.M.D.; Bortolin, T.; Canever, L.; Petronilho, F.; Mina, F.G.; Dal-Pizzol, F.; Quevedo, J.;
Zugno, A.I. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats.
Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 2009, 33, 1003–1008. [CrossRef] [PubMed]
26. Nabavi, S.M.; Nabavi, S.F.; Eslami, S.; Moghaddam, A.H. In vivo protective effects of quercetin against
sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem. 2012, 132, 931–935. [CrossRef]
27. Doucet, D. Estrogen receptor hormone agonists limit trauma hemorrhage shock-induced gut and lung injury
in rats. PLoS ONE 2010, 5, e9421. [CrossRef] [PubMed]
28. Rönn, T. A new model of severe hemorrhagic shock in rats. Comp. Med. 2011, 61, 419–426. [PubMed]
29. Mangala, A.; Nadkarni, A. Determination of bacterial load by real-time PCR using a broad-range (universal)
probe and primers set. Microbiology 2002, 148, 257–266.
Sample Availability: Available from the authors.
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
